Cargando…

Prospects of Curcumin Nanoformulations in Cancer Management

There is increasing interest in the use of natural compounds with beneficial pharmacological effects for managing diseases. Curcumin (CUR) is a phytochemical that is reportedly effective against some cancers through its ability to regulate signaling pathways and protein expression in cancer developm...

Descripción completa

Detalles Bibliográficos
Autores principales: Amekyeh, Hilda, Alkhader, Enas, Sabra, Rayan, Billa, Nashiru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777756/
https://www.ncbi.nlm.nih.gov/pubmed/35056675
http://dx.doi.org/10.3390/molecules27020361
_version_ 1784637143410278400
author Amekyeh, Hilda
Alkhader, Enas
Sabra, Rayan
Billa, Nashiru
author_facet Amekyeh, Hilda
Alkhader, Enas
Sabra, Rayan
Billa, Nashiru
author_sort Amekyeh, Hilda
collection PubMed
description There is increasing interest in the use of natural compounds with beneficial pharmacological effects for managing diseases. Curcumin (CUR) is a phytochemical that is reportedly effective against some cancers through its ability to regulate signaling pathways and protein expression in cancer development and progression. Unfortunately, its use is limited due to its hydrophobicity, low bioavailability, chemical instability, photodegradation, and fast metabolism. Nanoparticles (NPs) are drug delivery systems that can increase the bioavailability of hydrophobic drugs and improve drug targeting to cancer cells via different mechanisms and formulation techniques. In this review, we have discussed various CUR-NPs that have been evaluated for their potential use in treating cancers. Formulations reviewed include lipid, gold, zinc oxide, magnetic, polymeric, and silica NPs, as well as micelles, dendrimers, nanogels, cyclodextrin complexes, and liposomes, with an emphasis on their formulation and characteristics. CUR incorporation into the NPs enhanced its pharmaceutical and therapeutic significance with respect to solubility, absorption, bioavailability, stability, plasma half-life, targeted delivery, and anticancer effect. Our review shows that several CUR-NPs have promising anticancer activity; however, clinical reports on them are limited. We believe that clinical trials must be conducted on CUR-NPs to ensure their effective translation into clinical applications.
format Online
Article
Text
id pubmed-8777756
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87777562022-01-22 Prospects of Curcumin Nanoformulations in Cancer Management Amekyeh, Hilda Alkhader, Enas Sabra, Rayan Billa, Nashiru Molecules Review There is increasing interest in the use of natural compounds with beneficial pharmacological effects for managing diseases. Curcumin (CUR) is a phytochemical that is reportedly effective against some cancers through its ability to regulate signaling pathways and protein expression in cancer development and progression. Unfortunately, its use is limited due to its hydrophobicity, low bioavailability, chemical instability, photodegradation, and fast metabolism. Nanoparticles (NPs) are drug delivery systems that can increase the bioavailability of hydrophobic drugs and improve drug targeting to cancer cells via different mechanisms and formulation techniques. In this review, we have discussed various CUR-NPs that have been evaluated for their potential use in treating cancers. Formulations reviewed include lipid, gold, zinc oxide, magnetic, polymeric, and silica NPs, as well as micelles, dendrimers, nanogels, cyclodextrin complexes, and liposomes, with an emphasis on their formulation and characteristics. CUR incorporation into the NPs enhanced its pharmaceutical and therapeutic significance with respect to solubility, absorption, bioavailability, stability, plasma half-life, targeted delivery, and anticancer effect. Our review shows that several CUR-NPs have promising anticancer activity; however, clinical reports on them are limited. We believe that clinical trials must be conducted on CUR-NPs to ensure their effective translation into clinical applications. MDPI 2022-01-07 /pmc/articles/PMC8777756/ /pubmed/35056675 http://dx.doi.org/10.3390/molecules27020361 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Amekyeh, Hilda
Alkhader, Enas
Sabra, Rayan
Billa, Nashiru
Prospects of Curcumin Nanoformulations in Cancer Management
title Prospects of Curcumin Nanoformulations in Cancer Management
title_full Prospects of Curcumin Nanoformulations in Cancer Management
title_fullStr Prospects of Curcumin Nanoformulations in Cancer Management
title_full_unstemmed Prospects of Curcumin Nanoformulations in Cancer Management
title_short Prospects of Curcumin Nanoformulations in Cancer Management
title_sort prospects of curcumin nanoformulations in cancer management
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777756/
https://www.ncbi.nlm.nih.gov/pubmed/35056675
http://dx.doi.org/10.3390/molecules27020361
work_keys_str_mv AT amekyehhilda prospectsofcurcuminnanoformulationsincancermanagement
AT alkhaderenas prospectsofcurcuminnanoformulationsincancermanagement
AT sabrarayan prospectsofcurcuminnanoformulationsincancermanagement
AT billanashiru prospectsofcurcuminnanoformulationsincancermanagement